✦ LIBER ✦

Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma

✍ Scribed by Kensei Tobinai; Ken-ichi Ishizawa; Michinori Ogura; Kuniaki Itoh; Yasuo Morishima; Kiyoshi Ando; Masafumi Taniwaki; Takashi Watanabe; Joji Yamamoto; Toshiki Uchida; Masanobu Nakata; Takashi Terauchi; Shigeru Nawano; Masaki Matsusako; Masaki Hayashi; Tomomitsu Hotta

Book ID: 108586458
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 955 KB
Volume: 100
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2009.01247.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of fludarabine, bortezomib

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

✍ Paul M. Barr; Pingfu Fu; Hillard M. Lazarus; Nancy Horvath; Stanton L. Gerson; O 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Multicenter phase II study of bendamusti

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

✍ Ken Ohmachi; Kiyoshi Ando; Michinori Ogura; Toshiki Uchida; Kuniaki Itoh; Nobuko 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB

Rituximab monotherapy with eight weekly

Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

✍ Kensei Tobinai; Tadahiko Igarashi; Kuniaki Itoh; Mitsutoshi Kurosawa; Hirokazu N 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

Phase II trial of the combination of den

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

✍ Nam H. Dang; Luis Fayad; Peter McLaughlin; Jorge E. Romaguara; Fredrick Hagemeis 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB

Pixantrone dimaleate in combination with

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma : Phase 1 study with a dose-expansion cohort

✍ Tomasz P. Srokowski; James E. Liebmann; Manuel R. Modiano; Gary I. Cohen; Barbar 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

## Abstract ## BACKGROUND: Pixantrone dimaleate (pixantrone) has been shown to have antitumor activity in leukemia and lymphoma in vitro models and to lack delayed cardiotoxicity associated with mitoxantrone in animal models. FND‐R, a combination regimen of fludarabine, mitoxantrone, dexamethasone

Phase I and pharmacokinetic study of ben

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

✍ Michinori Ogura; Toshiki Uchida; Masafumi Taniwaki; Kiyoshi Ando; Takashi Watana 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB